GlassScriptPhysician profile
Rehmat Sheikh
NPI 1457516965
$2,489.66
in general payments reported to CMS, 2019-2025
15 companies · $59.97 in 2025
The $59.97 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $126 · 2021: $346 · 2022: $641 · 2023: $43.53 · 2024: $252 · 2025: $59.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $845.87 | 2021-2022 | |
| Medtronic Vascular, INC. | $707.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $206.88 | 2019-2025 | |
| Abiomed | $192.47 | 2021-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.99 | 2019-2021 | |
| Abbott Laboratories | $82.83 | 2020-2024 | Dragonfly Opstar |
| Janssen Pharmaceuticals, INC | $77.50 | 2019-2021 | |
| Penumbra, INC. | $65.65 | 2024 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $41.03 | 2019-2021 | |
| Edwards Lifesciences Corporation | $37.71 | 2024 | |
| Boston Scientific Corporation | $25.10 | 2025 | Watchman Flx |
| Amarin Pharma, INC. | $22.74 | 2019 | |
| Pfizer INC. | $16.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehmat Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.